Cargando…

The effect of basal–bolus therapy varies with baseline 1,5‐anhydroglucitol level in people with Type 2 diabetes: a post hoc analysis

AIMS: To investigate the impact of baseline 1,5‐anhydroglucitol on the treatment effect of basal–bolus therapy in people with Type 2 diabetes. METHODS: Post hoc analysis of onset 3, an 18‐week, randomized, phase 3 trial evaluating the efficacy and safety of fast‐acting insulin aspart in basal–bolus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heller, S., Bowering, K., Raskin, P., Liebl, A., Buchholtz, K., Gorst‐Rasmussen, A., Pieber, T. R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099439/ https://www.ncbi.nlm.nih.gov/pubmed/29802636 http://dx.doi.org/10.1111/dme.13693

Ejemplares similares

Efficacy and Safety of Fast-Acting Insulin Aspart in People with Type 1 Diabetes Using Carbohydrate Counting: A Post Hoc Analysis of Two Randomised Controlled Trials
por: Rose, Ludger, et al.
Publicado: (2019)

An Indirect Comparison of Basal Insulin Plus Once-Weekly Semaglutide and Fully Optimised Basal–Bolus Insulin in Type 2 Diabetes
por: Lingvay, Ildiko, et al.
Publicado: (2022)

Association of 1,5-Anhydroglucitol With Cardiovascular Disease and Mortality
por: Selvin, Elizabeth, et al.
Publicado: (2016)

Transitioning from basal–bolus or premix insulin therapy to a combination of basal insulin and glucagon‐like peptide‐1 receptor agonist in people with type 2 diabetes
por: Mehta, Roopa, et al.
Publicado: (2022)

Data for serum 1,5 anhydroglucitol concentration in different populations
por: Welter, Marciane, et al.
Publicado: (2018)

1,5-Anhydroglucitol as a Marker of Acute Hyperglycemia in Cardiovascular Events
por: Migała, Marta, et al.
Publicado: (2022)

Baseline nocturnal glucose change: A predictor of the treatment effect of bolus intensification in insulin‐treated type 2 diabetes
por: Peters, Anne L., et al.
Publicado: (2019)

Value of serum 1,5-anhydroglucitol measurements in childhood obesity in the continuum of diabetes
por: Yoo, Ha Yeong, et al.
Publicado: (2015)

Rational diagnoses of diabetes: the comparison of 1,5-anhydroglucitol with other glycemic markers
por: Malkan, Umit Yavuz, et al.
Publicado: (2015)

Salivary 1,5-Anhydroglucitol and Vitamin Levels in Relation to Caries Risk in Children
por: Syed, Sadatullah, et al.
Publicado: (2019)

Finding the clinical utility of 1,5-anhydroglucitol among primary care practitioners
por: Peabody, John, et al.
Publicado: (2020)

Investigating the Association Between Baseline Characteristics (HbA1c and Body Mass Index) and Clinical Outcomes of Fast-Acting Insulin Aspart in People with Diabetes: A Post Hoc Analysis
por: Bowering, Keith, et al.
Publicado: (2018)

Association between a biomarker of glucose spikes, 1,5-anhydroglucitol, and cancer mortality
por: Kira, Sakurako, et al.
Publicado: (2020)

Evaluation of Serum 1,5 Anhydroglucitol Levels as a Clinical Test to Differentiate Subtypes of Diabetes
por: Pal, Aparna, et al.
Publicado: (2010)

Alternative biomarkers for assessing glycemic control in diabetes: fructosamine, glycated albumin, and 1,5-anhydroglucitol
por: Lee, Ji-Eun
Publicado: (2015)

Measurement of 1,5-anhydroglucitol in blood and saliva: from non-targeted metabolomics to biochemical assay
por: Halama, Anna, et al.
Publicado: (2016)

1,5-Anhydroglucitol Predicts Mortality in Patients with HBV-Related Acute-on-chronic Liver Failure
por: Zhang, Lingjian, et al.
Publicado: (2022)

Association of 1,5-Anhydroglucitol and 2-h Postprandial Blood Glucose in Type 2 Diabetic Patients
por: Stettler, Christoph, et al.
Publicado: (2008)

Effect of 1,5-anhydroglucitol levels on culprit plaque rupture in diabetic patients with acute coronary syndrome
por: Su, Gong, et al.
Publicado: (2020)

Salivary 1,5-Anhydroglucitol and its Correlation with Postprandial Hyperglycemia: Development and Validation of a Novel Assay
por: Kedarnath, Priyadarshini Subramaniam, et al.
Publicado: (2023)

Serum levels of 1,5-anhydroglucitol and 1,5-anhydrofructose-derived advanced glycation end products in patients undergoing hemodialysis
por: Tanaka, Kenji, et al.
Publicado: (2021)

The basal to total insulin ratio in outpatients with diabetes on basal-bolus regimen
por: Castellano, Elena, et al.
Publicado: (2018)

1,5-Anhydroglucitol as a Useful Marker for Assessing Short-Term Glycemic Excursions in Type 1 Diabetes
por: Seok, Hannah, et al.
Publicado: (2015)

Genome-wide association study of 1,5-anhydroglucitol identifies novel genetic loci linked to glucose metabolism
por: Li, Man, et al.
Publicado: (2017)

Human and mouse non‐targeted metabolomics identify 1,5‐anhydroglucitol as SGLT2‐dependent glycemic marker
por: Kappel, Ben A., et al.
Publicado: (2021)

Saliva 1,5-anhydroglucitol is associated with early-phase insulin secretion in Chinese patients with type 2 diabetes
por: Ying, Lingwen, et al.
Publicado: (2021)

SGLT5 is the renal transporter for 1,5-anhydroglucitol, a major player in two rare forms of neutropenia
por: Diederich, Jennifer, et al.
Publicado: (2023)

Correction to: The basal to total insulin ratio in outpatients with diabetes on basal-bolus regimen
por: Castellano, Elena, et al.
Publicado: (2018)

1,5-Anhydroglucitol as a marker of maternal glycaemic control and predictor of neonatal birthweight in pregnancies complicated by type 1 diabetes mellitus
por: Nowak, N., et al.
Publicado: (2013)

Association between 1,5-Anhydroglucitol and Acute C Peptide Response to Arginine among Patients with Type 2 Diabetes
por: Shen, Yun, et al.
Publicado: (2020)

Nonlinear association of 1,5-anhydroglucitol with the prevalence and severity of coronary artery disease in chinese patients undergoing coronary angiography
por: Yang, Ruiyue, et al.
Publicado: (2022)

An Efficient Electrochemical Biosensor to Determine 1,5-Anhydroglucitol with Persimmon-Tannin-Reduced Graphene Oxide-PtPd Nanocomposites
por: Li, Guiyin, et al.
Publicado: (2023)

Differential Treatment Response to Insulin Intensification Therapy: A Post Hoc Analysis of a Randomized Trial Comparing Premixed and Basal-Bolus Insulin Regimens
por: Shi, Li Xin, et al.
Publicado: (2017)

Continuous Glucose Monitoring Sensor Glucose Levels and Insulin Pump Infusion Set Wear-Time During Treatment with Fast-Acting Insulin Aspart: A Post Hoc Analysis of Onset 5
por: Gorst-Rasmussen, Anders, et al.
Publicado: (2022)

A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naïve People With Type 2 Diabetes: A randomized, controlled trial
por: Heise, Tim, et al.
Publicado: (2011)

A study on the association of serum 1,5-anhydroglucitol levels and the hyperglycaemic excursions as measured by continuous glucose monitoring system among people with type 2 diabetes in China
por: Wang, Y, et al.
Publicado: (2012)

Rare variants in SLC5A10 are associated with serum 1,5-anhydroglucitol (1,5-AG) in the Atherosclerosis Risk in Communities (ARIC) Study
por: Loomis, Stephanie J., et al.
Publicado: (2019)

1,5-Anhydroglucitol, an indicator of short term glycaemic control, is the most discriminatory metabolomic marker in adolescents with type 1 diabetes compared to control subjects
por: Conwell, Louise S, et al.
Publicado: (2015)

Clinical Application of 1,5-Anhydroglucitol Measurements in Patients with Hepatocyte Nuclear Factor-1α Maturity-Onset Diabetes of the Young
por: Skupien, Jan, et al.
Publicado: (2008)

Serum 1,5-anhydroglucitol when used with fasting plasma glucose improves the efficiency of diabetes screening in a Chinese population
por: Ying, Lingwen, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5phktblb70jc0g02pp9en7u54b